Targeted Protein Stabilization Therapy for Neurodegeneration

Migration, Crosslink

📖

Targeted Protein Stabilization Therapy for Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-targeted-protein-stabi

📖 Wiki Page

therapeutic686 wordssynced 2026-04-02

Targeted Protein Stabilization Therapy for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Targeted Protein Stabilization Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target Proteins</td>
<td>[Tau](/proteins/tau), α-syn, [HTT](/proteins/htt-protein), SOD1, [TDP-43](/proteins/tdp-43)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Stabilization, aggregation inhibition, clearance enhancement</td>
</tr>
<tr>
<td class="label">Target Diseases</td>
<td>AD, PD, HD, ALS, FTLD</td>
</tr>
<tr>
<td class="label">Clinical Status</td>
<td>Preclinical to Phase II</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lithobetter</td>
<td>GSK-3β inhibitor</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>GSK-3β inhibitor</td>
</tr>
<tr>
<td class="label">Saracatinib</td>
<td>Fyn inhibitor</td>
</tr>
<tr>
<td class="label">Methylene blue</td>
<td>Aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Anle138b</td>
<td>Aggregation inhibitor</td>
</tr>
<tr>
<td class="label">CLR01</td>
<td>Aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Synuclein inh

...

Targeted Protein Stabilization Therapy for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Targeted Protein Stabilization Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target Proteins</td>
<td>[Tau](/proteins/tau), α-syn, [HTT](/proteins/htt-protein), SOD1, [TDP-43](/proteins/tdp-43)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Stabilization, aggregation inhibition, clearance enhancement</td>
</tr>
<tr>
<td class="label">Target Diseases</td>
<td>AD, PD, HD, ALS, FTLD</td>
</tr>
<tr>
<td class="label">Clinical Status</td>
<td>Preclinical to Phase II</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lithobetter</td>
<td>GSK-3β inhibitor</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>GSK-3β inhibitor</td>
</tr>
<tr>
<td class="label">Saracatinib</td>
<td>Fyn inhibitor</td>
</tr>
<tr>
<td class="label">Methylene blue</td>
<td>Aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Anle138b</td>
<td>Aggregation inhibitor</td>
</tr>
<tr>
<td class="label">CLR01</td>
<td>Aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Synuclein inhibitors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Copper bis(thiosemicarbazone)</td>
<td>Cu/Zn delivery</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSP90 co-inducer</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate/taurursodiol</td>
<td>[UPR](/entities/unfolded-protein-response) induction</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">P110</td>
<td>HTT aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Various</td>
</tr>
</table>

Targeted Protein Stabilization Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Protein homeostasis disruption is central to neurodegeneration. Targeted protein stabilization aims to maintain proper protein folding, prevent aggregation, and restore proteostasis using small molecules, peptides, and biologics. [@alphasynuclein]

Overview

Mermaid diagram (expand to render)

Protein Misfolding in Neurodegeneration

Tau Pathology (AD, CBD, PSP)

Hyperphosphorylation leads toNFT formation
Microtubule destabilization
Synaptic dysfunction

α-Synucleinopathy (PD, DLB, MSA)

Lewy body formation
Membrane pore formation
Membrane trafficking disruption

Huntington's Disease

Polyglutamine expansion
[HTT](/genes/htt) aggregation
Transcriptional dysregulation

ALS/FTLD

[TDP-43](/mechanisms/tdp-43-proteinopathy) mislocalization
FUS aggregation
Stress granule formation

Stabilization Strategies

Pharmacological Chaperones

Bind to misfolded proteins to promote proper folding:

Geldanamycin derivatives: HSP90 inhibitors (ATN-161, 17-AAG)
Epoxygenated fatty acids: EETs
Natural compounds: Curcumin, resveratrol

Allosteric Modulators

Bind to allosteric sites to stabilize native conformation:

[Tau](/proteins/tau): Lithium, [GSK-3β](/entities/gsk3-beta) inhibitors indirectly
SOD1: Copper chelation/loading

Kinetic Stabilization

Slow or prevent unfolding:

Tau: Tau aggregation inhibitors (LMTX, methylene blue)
α-syn: Small molecule inhibitors

Specific Approaches

Tau Stabilization

α-Syn Stabilization

SOD1 Stabilization

HTT Stabilization

Combination Approaches

Stabilization + Clearance: Combined approach

Chaperone + Proteostasis: Enhance native folding + degradation

Small molecule + Antibody: Multiple mechanisms

Clinical Trials

Active/Recent

NCT030华东68: Tideglusib in PSP (completed)
NCT0224558: Lithium in AD (completed)
NCT0379066: Arimoclomol in SOD1-ALS (Phase III)

Challenges

[Blood-brain barrier](/entities/blood-brain-barrier) penetration
Specificity for target protein
Maintaining long-term stability
Patient selection (genetic vs sporadic)

Biomarkers

Tau: CSF total/phospho-tau, PET ligands
α-syn: CSF α-syn, seeding assays
HTT: CSF mutant HTT, PET
SOD1: Activity assays, PET ligands (in development)

Future Directions

PROTAC-mediated stabilization: Instead of degradation
Gene therapy: Deliver chaperone genes
Protein engineering: Engineered chaperones
Multi-target approaches: Address multiple proteins
Precision medicine: Genotype-specific approaches

Background

The study of Targeted Protein Stabilization Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[Nature Chemical Biology - Protein Stabilization](https://www.nature.com/subjects/chemical-biology)
[Cell - Protein Quality Control](https://www.cell.com/subjects/protein-quality-control)
[NIH - Protein Folding Research](https://www.nigms.nih.gov/Research/Topics/ProteinFolding)

External Links

[NIH Protein Stability Database](https://proteinstability.org)
[PROTAC Database](http://protac-database.com)
[Molecular Chaperone Research](https://chaperone-research.org)

References

[Unknown, - Tau aggregation inhibitors (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28765434/)

[Unknown, - Alpha-synuclein aggregation inhibitors (n.d.)](https://pubmed.ncbi.nlm.nih.gov/27654322/)

[Unknown, - Pharmacological chaperones for neurodegeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29345680/)

[Unknown, - Arimoclomol in ALS (n.d.)](https://pubmed.ncbi.nlm.nih.gov/31234569/)

[Unknown, - SOD1 stabilization strategies (n.d.)](https://pubmed.ncbi.nlm.nih.gov/30123459/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-targeted-protein-stabilization-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-targeted-protein-stabilization-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-de75c736f051
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-targeted-protein-stabilization-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

551

Outgoing

721

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Targeted Protein Stabilization Therapy for Neurodegeneration

Targeted Protein Stabilization Therapy for Neurodegeneration

Introduction

Targeted Protein Stabilization Therapy for Neurodegeneration

Introduction

Overview

Protein Misfolding in Neurodegeneration

Tau Pathology (AD, CBD, PSP)

α-Synucleinopathy (PD, DLB, MSA)

Huntington's Disease

ALS/FTLD

Stabilization Strategies

Pharmacological Chaperones

Allosteric Modulators

Kinetic Stabilization

Specific Approaches

Tau Stabilization

α-Syn Stabilization

SOD1 Stabilization

HTT Stabilization

Combination Approaches

Clinical Trials

Active/Recent

Challenges

Biomarkers

Future Directions

Background

See Also

External Links

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Targeted Protein Stabilization Therapy for Neurodegeneration

Targeted Protein Stabilization Therapy for Neurodegeneration

Introduction

Targeted Protein Stabilization Therapy for Neurodegeneration

Introduction

Overview

Protein Misfolding in Neurodegeneration

Tau Pathology (AD, CBD, PSP)

α-Synucleinopathy (PD, DLB, MSA)

Huntington's Disease

ALS/FTLD

Stabilization Strategies

Pharmacological Chaperones

Allosteric Modulators

Kinetic Stabilization

Specific Approaches

Tau Stabilization

α-Syn Stabilization

SOD1 Stabilization

HTT Stabilization

Combination Approaches

Clinical Trials

Active/Recent

Challenges

Biomarkers

Future Directions

Background

See Also

External Links

See Also

External Links

References

Related Hypotheses

💬 Discussion